
Principles and Practice of Clinical Electrophysiology of Vision

Editors

JOHN R. HECKENLIVELY, M.D.
Professor of Ophthalmology
Jules Stein Eye Institute
Los Angeles, California

GEOFFREY B. ARDEN, M.D., PH.D.
Professor of Ophthalmology and
Neurophysiology
Institute of Ophthalmology
Moorfields Eye Hospital
London, England

Associate Editors

EMIKO ADACHI-USAMI, M.D.
Professor of Ophthalmology
Chiba University School of Medicine
Chiba, Japan

G.F.A. HARDING, PH.D.
Professor of Neurosciences
Department of Vision Sciences
Aston University
Birmingham, England

SVEN ERIK NILSSON, M.D., PH.D.
Professor of Ophthalmology
University of Linköping
Linköping, Sweden

RICHARD G. WELEBER, M.D.
Professor of Ophthalmology
University of Oregon Health Science Center
Portland, Oregon

 **Mosby
Year Book**

St. Louis Baltimore Boston Chicago London Philadelphia Sydney Toronto



Dedicated to Publishing Excellence

Sponsoring Editor: David K. Marshall
Assistant Director, Manuscript Services: Frances M. Perveiler
Production Project Coordinator: Karen E. Halm
Proofroom Manager: Barbara Kelly

Copyright © 1991 by Mosby-Year Book, Inc.
A Year Book Medical Publishers imprint of Mosby-Year Book, Inc.

Mosby-Year Book, Inc.
11830 Westline Industrial Drive
St. Louis, MO 63146

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without prior written permission from the publisher. Printed in the United States of America.

Permission to photocopy or reproduce solely for internal or personal use is permitted for libraries or other users registered with the Copyright Clearance Center, provided that the base fee of \$4.00 per chapter plus \$.10 per page is paid directly to the Copyright Clearance Center, 21 Congress Street, Salem, MA 01970. This consent does not extend to other kinds of copying, such as copying for general distribution, for advertising or promotional purposes, for creating new collected works, or for resale.

1 2 3 4 5 6 7 8 9 0 CL CL MV 95 94 93 92 91

Library of Congress Cataloging-in-Publication Data

Principles and practice of visual electrophysiology / [edited by]
John R. Heckenlively, Geoffrey B. Arden.

p. cm.

Includes bibliographical references.

Includes index.

ISBN 0-8151-4290-0

1. Electroretinography. 2. Electrooculography. 3. Visual evoked response. I. Heckenlively, John R. II. Arden, Geoffrey B. (Geoffrey Bernard)

[DNLM: 1. Electrooculography. 2. Electrophysiology.

3. Electroretinography. 4. Evoked Potentials, Visual. 5. Vision

Disorders—physiopathology. WW 270 P957]

RE79.E4P75 1991

617.7 1547—dc20

DNLM/DLC

for Library of Congress

91-13378

CIP

Index

A

- Abetalipoproteinemia:
 - hereditary,
 - electroretinography in, 506
- Absolute threshold, 445
- Abuse: drugs of, and visual nervous system, 170
- Accommodation
 - aging and, 423
 - amplitude, objective, 423
- Action potentials: from on/off ganglion cell, 367
- Acuity
 - (*See also* Visual acuity)
 - grating
 - in infant, 408–409
 - tests, 462
 - monocular, measurement, 413
 - relation of visual evoked potentials to, 136
 - vernier, in infant, 409–410
- Adaptation
 - dark (*see* Dark adaptation)
 - effects in
 - electroretinography, 391–395
 - light (*see* Light adaptation)
- Adaptometry, dark, 449–454
 - in thioridazine retinopathy, 604
 - two-color, in vitamin A deficiency, 739
- Adenoma: chromophobe, 559
- Adenosine: retinal effects of, 156–157
- Adrenergic
 - beta- (*See* Beta-adrenergic)
 - transmitters,
 - beta-adrenergic
 - antagonists action to, 156
- Age
 - changes in visual evoked cortical potentials, 417–420
 - effect of, in
 - electroretinography, 376
 - electroretinography and, pattern, 294
 - of onset
 - of retinitis pigmentosa, 519–520
 - of Stargardt's disease, 669–670
 - P100 peak latency and, 420
- Agglutinin: peanut
 - agglutinin-binding molecules, 58
- Aging
 - accommodations and, 423
 - contrast thresholds and, 420–421
 - luminance threshold and, 421–422
 - peak latency changes with, 418–420
 - pupillary size and, 423
 - temporal frequency characteristics and, 420
 - visual evoked cortical potential and, pattern, 417–424
- Albinism, 425–434, 773–782
 - data analysis, 433
 - electrode montage in, 427, 433
 - genotype in, 774
 - luminance flash in, 432
 - pattern-onset in, 429, 431
 - response, analysis
 - procedures in, 427
 - pattern onset and offset, 426, 432
 - pedigree in, 777, 778
 - phenotype in, 774
 - stimulus mode for, 433
 - test protocol, 433
 - testing methodology, 425–434
 - visual evoked cortical potentials in, methods, overview, 433
 - visual evoked potential topography in, 430
- Alcoholism, 575
- Alpha-aminoadipic acid, 103
- Alzheimer's disease
 - electroretinography in, pattern, 795
 - evoked potentials in, 793–796
- Amacrine cells: in retina (in monkey), 36
- Amblyopia: and clinical electrophysiology, 589–593
- α -Aminoadipic acid, 103
- Amplification
 - double-sided, principle of, 387
- synchronous, 250–252
- system, standard in ERG, 287
- Amplifiers, 183–188
 - alternating current, 185
 - bias, 185
 - calibration of, 194–195
 - direct current, 185
 - double-sided, and mains hum reduction, 386–387
 - dynamic range, 185
 - frequency response function, 186
 - gain of, 185
 - impedance, input and output, 185
 - linearity, 185
 - phase distortion and, 187–188
 - preamplifiers, 183–185
 - saturation, artifacts in, 389–390
- Amplitude
 - aging and, changes, 417–418
 - objective, of
 - accommodation, 423
- Analog filters, 186–187
- Analysis, 229–276
 - data, 229–276
 - Fourier (*see* Fourier analysis)
 - kernel (*see* Kernel)
 - signal (*see* Signal analysis)
 - system, and
 - cross-correlation, 248–249

Analysis (*cont.*)

- techniques, 231–253
 - correlation with noise and power spectrum, 246–249
- Anesthetics: and visual nervous system, 169
- Angiography, fluorescein, 494–500
 - as adjunct to electrophysiological testing, 494–500
 - in atrophy gyrate, 654
 - in Bietti's crystalline dystrophy, 684, 686
 - in choroideremia, 494–496, 660, 661
 - carrier, 663
 - dark choroid effect and, 497–499
 - in diabetic retinopathy, 626, 628, 629, 632
 - in macular schisis vs. edema, 496–497
 - of maculopathy, 672
 - in night blindness, incomplete-type, 722, 724
 - in optic atrophy with disc telangiectasia, 499
 - in pattern dystrophy/retinal pigment epithelium disease, 497
 - principles of, basic, 494
 - in reticular dystrophy, 701
 - in retinal diseases, hereditary, 494–500
 - in retinitis pigmentosa, preserved
 - para-arteriolar retinal pigment epithelial, 497
 - in Stargardt's disease, 670, 671–672
 - in Usher syndrome, type I, 496
- Anticholinergics: and visual nervous system, 169
- Antiepileptics: and visual nervous system, 169
- Arden ratios, 644
- Arteries (*see* Retina, artery)
- Artifact(s)
 - in amplifier saturation, 389–390
 - causes, 384–390
 - cures, 384–390
 - eye movements, 388–389
 - muscle, 388–389
 - occurring in new clinic, 384–385
 - recognition in visual evoked cortical potential recording, 438–439

- rejection, 195
- Astrocyte: in retina (in cat), 39
- Atrophy
 - fovea (*see* Fovea, atrophy)
 - gyrate
 - angiography of, fluorescein, 654
 - of choroid and retina (*see below*)
 - dark adaptation curves in, 654
 - Goldmann perimetry in, 653
 - muscle biopsy in, 655
 - pyridoxine-responsive, 650–651, 652
 - gyrate, of choroid and retina, 649–658
 - biochemistry, 653–655
 - clinical description, 651
 - diagnosis, differential, 656
 - genetics of, molecular, 655–656
 - histopathology, 651–652
 - history of disease, 649–651
 - natural history, 651
 - physiology, 652–653
 - testing in, relevant, 656
 - optic (*see* Optic atrophy)
- Autocorrelation, 246–247
 - functions of, 247
- Autosomal
 - dominant cone dystrophy, 542
 - recessive cone dystrophy, 542
- Averaging, 249–250
 - practical considerations on, 250
- response fluctuations, 250
- signal-noise ratio
 - improvement with, 249–250
- small signals, 389–390
- stimulus for, 249

- a-wave
 - amplitude, drugs reducing, 168
 - in retinal damage, 534

B

- Background illumination (*see* Illumination, background)
- b/a-wave amplitude ratios: in retinal vascular disease, 531–536
- Best's disease, 692–699
 - clinical observations, 692
 - diagnosis, differential, 692–693
 - electro-oculography in, 695, 696–697
 - electrophysiological tests in, 694–696
 - fundus in, 693
 - histopathology, 693–694
 - linkage analysis, 694
 - stages of, 693
 - synonyms, 693
- Beta-adrenergic
 - agonists, action of, 156
 - antagonists, action to adrenergic transmitters, 156
 - mechanisms in retina, 155–156
- Beta₂-adrenergic agonists: clenbuterol as, 155
- Bicarbonate responses, 163–166
- Bietti's crystalline dystrophy
 - of cornea and retina, 495, 683–691
 - clinical description, 683–689
 - cornea in, 689
 - diagnosis, differential, 690
 - findings in, 690
 - Ganzfeld ERGs in, 688
 - Goldmann perimetric visual fields for, 685, 686, 687
 - histopathology, 689
 - history, 683
 - natural history, 683–689
 - physiology, 689
 - relevant testing, 690
 - ultrastructure in, 689, 690
- Binary sequence control: effect of, 257
- Biology: retinal cell, principles of, 23–84
- Biopsy: muscle, in gyrate atrophy, 655
- Birdshot chorioretinitis, 640–642
 - fundus in, 641
- Blindness
 - color, early receptor potential in, 319
 - cortical, 578–580
 - causes, 578
 - retrochiasmal lesions and, 562
 - visual evoked cortical potentials in, 578–580
 - visual evoked cortical potentials in, works reporting abnormal potentials, 579
 - visual evoked cortical potentials in, works reporting normal potentials, 579

- visual evoked cortical potentials in, works reporting potentials recovery with visual improvements, 579–580
- visual signs, general clinical, 578
- night (*see* Night blindness)
- Blue cone monochromatism, 753–755
- Bone spicule: after chloroquine, 595
- Buffer process: K⁺ spatial, of glial cell, 88
- Buffering: K⁺ spatial, 87–88
- Burian-Allen
 - contact lens, 381
 - electrodes, problems with, 381–382
- b-wave, 101–111
 - amplitudes of, 289 (in cat), 102
 - drugs increasing, 168
 - drugs reducing, 168
 - linear regression, 378–379
 - reduction, relationship to Ganzfeld fields, 393
 - rod, change in dark after Ganzfeld field, 394
 - V-log intensity curves of, 154
- beta-adrenergic agents and, 156
- cone
 - amplitude, 349
 - implicit time, 349
 - implicit time
 - distributions, 350
 - implicit time, relationship to Ganzfeld fields, 393
 - implicit time, scatter plot and linear regression, 350
- current source density profiles, 104, 105
- DC component of, 108–109
- generation
 - alternate theories, 108
 - mechanism of, 103–105
- implicit times, 289
- in retinal vein occlusion, central, 617
- for retinal vein occlusion, central, with NVI, 615
- in lipofuscinosis, neuronal ceroid, 790
- Müller cell origin of, 101–103
- alpha-aminoadipic acid, 103

- current source density
 - analysis, 101
 - intracellular recording, 101–103
 - in retinal damage, 534
 - rod vs. cone, 109
 - scotopic, in diabetic retinopathy, 622–623
- C**
- Calcium concentration: at synaptic terminal of rod, 77
 - Calibration, 193–204
 - of amplifiers, 194–195
 - of delays due to filtering, 195
 - of flash
 - with digital photometer, 202
 - luminance with subjective photometer, 202
 - of gain, 194–195
 - procedures in electroretinography, 382
 - Carrier
 - detection, introduction to, 709–710
 - state in congenital stationary night blindness, 711–712
 - Cataract
 - effect on electroretinography, 379
 - focal ERG in, 336–337
 - in juvenile neuronal ceroid lipofuscinosis, 788
 - Cathode ray tubes, 218
 - Cell
 - ganglion (*see* Ganglion cell)
 - glial (*see* Glial cell)
 - Müller (*see* Müller cell)
 - photoreceptor (*see* Photoreceptor cell)
 - pigmented epithelium of retina, cytology and function, 59
 - postsynaptic (*see* Postsynaptic cells)
 - retina (*see* Retina, cell)
 - rod, responses of, 78
 - Central nervous system
 - dysfunction, 761–813
 - Ceroid lipofuscinosis (*see* Lipofuscinosis, neuronal ceroid)
 - cGMP cascade: of phototransduction, 74
 - Checkerboard
 - contrast-reversing potential waveshapes elicited by, 269
 - Fourier analysis and, 244–246
 - stimuli, comparison with grating stimuli, 409
 - Chiasmal lesions, 557–560
 - Children
 - electroretinography of, under halothane, 378
 - Hospital for Sick Children Study in developmental delay, 582–583
 - lipofuscinosis (*see* Lipofuscinosis, neuronal ceroid, juvenile)
 - management for testing, 279–280
 - retinitis pigmentosa
 - inversa, juvenile-onset, 677
 - retinoschisis, 496
 - X-linked juvenile (*see* Retinoschisis, X-linked juvenile)
 - testing, 281–282
 - visual acuity estimation (*see* Infant, visual acuity estimation in)
 - Chloroquine
 - foveal atrophy after, 595
 - retinal toxicity due to, 594–599
 - Chlorpromazine, 604–605
 - Cholinergics: and visual nervous system, 169
 - Chorioretinitis, birdshot, 640–642
 - fundus in, 641
 - Choroid
 - atrophy, gyrate (*see* Atrophy, gyrate, of choroid)
 - dark choroid effect
 - angiography and, fluorescein, 497–499
 - in Stargardt's disease, 498
 - relationships in central retina, light micrograph of (in monkey), 54
 - Choroideremia, 659–663
 - angiography in, fluorescein, 494–496, 660, 661
 - carriers, 662–663
 - angiography in, fluorescein, 663
 - clinical findings in, 660–663
 - diagnosis, differential, 663
 - ERG parameters in, 662
 - in hemizygotes, male, 660–662
 - heterozygotes, 662–663
 - X-linked carrier state
 - evaluation, 744–747
 - Chromatic recordings: in electroretinography, 339–347
 - Chromaticity diagram: CIE 1931, 219
 - Chromophobe adenoma, 559
 - CIE 1931 chromaticity diagram, 219
 - Circuit(s)
 - equivalent
 - electrical, for current pathways in eye, 89
 - of postsynaptic cell, 81
 - retinal, scheme of, 152
 - specialized, 44–45
 - voltage drive, of flash stimulator, 223
 - Circuitry
 - for cone signals through retina, 41–43
 - for rod signals through retina, 39–41
 - Clenbuterol, 155
 - Clinical testing principles, 483–569
 - Coat's reaction: in simplex retinitis pigmentosa, 499
 - Color
 - blindness, early receptor potential in, 319
 - in ERG, pattern, 298
 - production, 218–219
 - sense abnormality in
 - multiple sclerosis, 807–808
 - stimuli
 - filters, 216–217
 - production of, 215–217
 - vision
 - disorders, and rod-cone interaction, suppressive, 472
 - in Leber's hereditary optic atrophy, 763
 - in Sorsby's fundus dystrophy, 705
 - visual evoked potential (*see* Visual evoked potential, cortical, color)
 - Common-mode rejection, 387
 - ratio, 185
 - Computer
 - program for band-pass filter, 205–206
 - simulation of
 - electro-oculography, 306
 - Conductance: changes mediated by
 - L-glutamate, 79–80
 - Cone
 - blue cone
 - monochromatism, 753–755
 - b-wave (*see* b-wave, cone) degeneration
 - clinical features, 539–541
 - with drusen, familial, and scotoma, 680
 - optic atrophy in, temporal, 541
 - partial, 542
 - signs and symptoms, 539–541
 - disorders, management of, 543
 - dysfunction, 537–543
 - hereditary forms, 537
 - hereditary forms, known, 541–542
 - partial, 542
 - syndromes, 512
 - dystrophy, 537–543
 - autosomal dominant, 542
 - autosomal recessive, 542
 - early potential receptor in, 319
 - electroretinography in, 538
 - fovea centralis atrophy in, 540
 - hereditary forms, known, 541–542
 - macula in, 540
 - progressive, 512
 - dystrophy, X-linked
 - recessive, 756–760
 - biochemistry, 757–758
 - clinical description, 756–757
 - diagnosis, differential, 758–760
 - Ganzfeld EOG in, 759
 - Ganzfeld ERGs in, 758
 - Goldmann-Weekers dark adaptometry in, 759
 - histopathology, 757–758
 - history of disease, 756
 - natural history, 756–757
 - pathophysiology, 757–758
 - testing in, 758–760
 - electroretinography (*see* Electroretinography, cone)
 - perimetry (*see* Perimetry, rod and cone)

- Cone (*cont.*)
 relative spectral
 absorbances of, 197
 of retina
 circulating current
 reduction, due to light
 flashes (in monkey),
 71
 cone-cone coupling, 76
 degeneration,
 progressive, 64
 electron micrograph of
 (in monkey), 29
 functional
 interconnections of,
 75–76
 matrix sheath,
 fluorescence light
 micrograph of, 62
 off-center pathways (in
 cat), 42
 on-center pathways (in
 cat), 42
 pedicle, electron
 micrograph of, 30
 pedicle, telodendria of,
 gap junction between
 two, 31
 photoreceptor density,
 49
 photoreceptor density,
 isodensity maps of, 49
 photoresponse spectral
 sensitivity of (in
 monkey), 72
 phototransduction in,
 69–75
 rod-cone coupling, 76
 signals, circuitry
 through, 41–43
 voltage changes
 produced by light
 flashes in (in turtle),
 70
 vs. rod b-wave, 109
 -rod (*see* Rod-cone)
 single-flash “cone
 response” in ERG, 288
 spectral sensitivity
 functions, 476
- Contact lens
 Burian-Allen, 381
 electrode(s), 178–179
 of Riggs, 10
 in electroretinography, 330
 stimulator, haptic, 608
- Contrast
 definition of, 465
 sensitivity
 measurement, 465–468
 testing methods, 468
 testing, producing
 stimuli for, 467–468
 testing, results, 468
- testing, results for
 temporal frequencies,
 468
 significance of, 465
 spatial, 467
 sensitivity, 468
 temporal, 466–467
 thresholds
 aging and, 420–421
 mean, 421
 vs. pupillary area, 422
- Cornea
 Bietti’s dystrophy (*see*
 Bietti’s crystalline
 dystrophy of cornea)
 direct dc recording of
 ERG, 330
 opacity, effect on
 electroretinography,
 379
 recording, direct,
 electrodes for, 180
 toxicity, 594
 Cross-correlation: and
 system analysis,
 248–249
 c-wave, 91–92
 in diseases of pigment
 epithelium, 545–546
 normal, 544–545
 “off,” 546
 Cyclic nucleotide cascade,
 72–73
- ## D
- Dark adaptation
 basic clinical, 449–454
 curve(s)
 in atrophy, gyrate, 654
 in drusen, 667
 in night blindness, 454
 normal, 451
 normal, typical, 450
 in Oguchi’s disease, 716
 in electroretinography, 375
 cone, 394
 rod, 394–395
 in fundus albipunctatus,
 718, 733
 psychophysical, in night
 blindness,
 incomplete-type, 721
 in retinitis pigmentosa, 520
 in retinoschisis, X-linked
 juvenile, 728
- Dark adaptometry (*see*
 Adaptometry, dark)
- Data
 acquisition, 229–276
 systems, special-purpose
 (*see* Special-purpose
 data acquisition
 systems)
- analysis (*see* Analysis)
- Defocusing: and
 pattern-onset
 stimulation, 439
- Dementia: senile, of
 Alzheimer’s type,
 pattern
 electroretinography in,
 795
- Depression: spreading, 130
- Deutan(s)
 patients, early receptor
 potential in, 344–346
 rapid off-response in,
 339–344
- Developmental delay,
 581–584
 clinical description, 581
 diagnosis, differential, 584
 electrophysiological
 findings, 581–583
 historical, 581–582
 Hospital for Sick
 Children Study,
 582–583
 electroretinography in,
 581–584
 pathophysiology,
 583–584
 P100 latency in, 583
 in prematurity, 586, 587
 visual evoked cortical
 potentials in, 581–584
 flash, 585–588
- Diabetes mellitus
 electroretinography to
 detect early functional
 abnormality, 624
 flash response in, 320
 retinopathy in (*see*
 Retinopathy, diabetic)
- Diamox responses, 163–166
- Digital
 filters, 186–187
 band-pass (*see* Filter,
 band-pass, digital)
 photometer for flash
 calibration, 202
- Diodes (*see* Light-emitting
 diodes)
- Disc telangiectasia: with
 optic atrophy, 499
- Display system: standard in
 ERG, 287
- Display tubes, 217–219
 color production, 218–219
 description, general, 217
 patterns/contrast
 production, 217–218
- Diurnal patterns: in visual
 evoked cortical
 potential recording, 438
- L-Dopa: and visual nervous
 system, 168
- Drugs
 of abuse and visual
 nervous system, 170
 a-wave amplitude and, 168
 b-wave amplitude and, 168
 neuropsychiatric, effects
 on visual nervous
 system, 167–173
 for psychiatric conditions,
 167–168
 and retinal
 electrophysiology,
 151–162
 concentration
 estimation, 152–153
 drug application,
 151–153
 experimental
 preparations, 151–153
 interpretations of effects,
 151–153
 systemic drugs and
 retinal side effects, 158
 toxicity pathogenesis, 598
 visual evoked potentials
 amplitude and, 168
- Drusen
 dark adaptation curves
 from, 667
 dominant, 664–668
 clinical findings,
 664–665
 definition, 664
 electrophysiology of,
 665–668
 psychophysics of,
 665–668
 electroretinography in, 667
 familial, with cone
 degeneration and
 scotoma, 680
 inherited, 668
 DTL fiber electrodes,
 179–180
 “Dummy patients:” diagrams
 of, 388
 Duplicity theory, 448–449
 d-wave, 112–114
 ERGs with (in mammal),
 113
- Dystrophy
 Bietti’s (*see* Bietti’s
 crystalline dystrophy)
 cone (*see* Cone dystrophy)
 pattern, 700–706
 clinical findings,
 700–701
 electro-oculography in,
 701, 704
 electroretinography in,
 703
 physiological findings,
 701–704
 pigmentation in, 703

- retinal pigment epithelium disease, 497
 - reticular, 701
 - rod-cone (*see* Rod-cone dystrophy)
 - Sorsby's fundus, 705
- E**
- Early receptor potential (*see* Receptor potential, early)
 - Edema, macular, 524
 - vs. schisis, fluorescein angiography in, 496–497
 - E-ERG analysis (in cat), 8
 - Einthoven and Jolly: ERG recording, 6
 - Electric current:
 - transretinal, retinal potentials evoked by, 129–130
 - Electrical
 - changes produced by light, 69–72
 - equivalent circuit for current pathways in eye, 89
 - Electrode(s), 177–182
 - Burian-Allen, problems with, 381–382
 - cleaning, standard in ERG, 285
 - contact lens, 178–179
 - of Riggs, 10
 - for corneal recording, direct, 180
 - DTL fiber, 179–180
 - electrode-oculogram, 180–181
 - for electrophysiological testing, 177–182
 - electroretinographic, 177–180
 - in electroretinography, pattern (*see* Electroretinography, pattern, electrodes)
 - gold foil lid-hook, 179
 - ground, standard in ERG, 285
 - impedance, measurement of, 194
 - montage in albinism, 427, 433
 - oculogram electrodes, 180–181
 - placements
 - standard, 92
 - for visual evoked cortical potential recording, 399–406
 - positions, ten-twenty designations of, 402–406
 - problems, 387–388
 - checking for, 388
 - recording, standard in ERG, 285
 - reference, standard in ERG, 285
 - skin, 180
 - standard in ERG, 285
 - stability, standard in ERG, 285
 - standards in ERG, 285–286
 - for visual evoked cortical potential recording, 399
 - visual evoked response, 181
 - in vitreous humor (in cat), 109
 - Electron micrograph
 - of cone of retina (in monkey), 29
 - pedicle, 30
 - of foveal neuropil, 35
 - of rods of retina (in monkey), 29
 - Electron microscopy: in lipofuscinosis, neuronal ceroid, juvenile, 789
 - Electronic
 - noise sources, 184
 - recording equipment, standard in ERG, 287
 - Electro-oculography, 301–313
 - applications, clinical, 308–309
 - in Best's disease, 695, 696–697
 - clinical, 301
 - computer stimulation of, 306
 - in diabetic retinopathy, 625
 - in dystrophy, pattern, 701, 704
 - eye movements, 302–303
 - in fundus albipunctatus, 734–735
 - history of, 14–16
 - light peak, 303–305
 - in melanoma, malignant, 644–645
 - models in, mathematical, 305–306
 - monitoring eye positions, 303
 - in night blindness, incomplete-type, 722
 - non-photoc stimuli, 307
 - oscillation
 - fast, 308
 - slow, 305, 307–308
 - principle of indirect recording, 301–302
 - response parameters, 305
 - special recording conditions, 306–307
 - Electrophosphenes:
 - comparison with magnetophosphenes, 365–366
 - Electrophysiology
 - amblyopia and, 589–593
 - of drusen, dominant, 665–668
 - in fundus flavimaculatus, 681
 - in inflammatory states, 611–645
 - of Leber's hereditary optic atrophy, 764
 - light-emitting diodes in (*see* Light-emitting diodes)
 - in lipofuscinosis, neuronal ceroid, 786–789
 - parameters in retinitis pigmentosa, 510–527
 - in pituitary syndromes, 783–785
 - recording systems, digital filter for, 205–210
 - of retina (*see* Retina, electrophysiology)
 - of Sorsby's fundus dystrophy, 706
 - stimulators for (*see* Stimulators for electrophysiology)
 - system, typical clinical, major components of, 190
 - testing
 - angiography, fluorescein, as adjunct (*see* Angiography, fluorescein)
 - in Best's disease, 694–696
 - definitive, examples of, 490
 - electrodes for, 177–182
 - equipment for, 175–228
 - lesion localization by, 486
 - psychophysical techniques relevant to, 445
 - tests, correlation of results with clinical findings, 491–492
 - in tumors, 611–645
 - in vascular disease, 611–645
 - visual, history of, 1–22
 - Electroretinography, 488
 - in abetalipoproteinemia, hereditary, 506
 - adaptation effects in, 391–395
 - amplitude(s)
 - distribution of, 289–290
 - photopic, histograms of, 290
 - background illumination in, 372
 - Burian-Allen electrode problems, 381–382
 - calibration procedures, 382
 - in children under halothane, 378
 - in choroideremia, 662
 - chromatic recordings of, 339–347
 - clinical, 9–11
 - components, 7–8
 - arising in retina, distal, 91–98
 - arising in retina, midretina, 99–100
 - arising in retina, proximal, 99–100
 - distal, interactions between, 97
 - putative underlying, 532
 - cone
 - effect of background illumination on, 392–394
 - dystrophy, 538
 - growth during light adaptation, 391–392
 - contact lens on eye, 330
 - c-wave of (*see* c-wave)
 - dark adaptation in, 375
 - initial, 287
 - in developmental delay, 581–584
 - in diabetes, to detect early functional abnormalities, 624
 - in diabetic retinopathy (*see* Retinopathy, diabetic, electroretinography in)
 - display unit, 331
 - in drusen, 667
 - duration series (in cat), 354
 - d-waves and (in mammal), 113
 - in dystrophy, pattern, 703
 - E-ERG analysis (in cat), 8
 - effect
 - of age, 376
 - of cataract, 379
 - of corneal opacity, 379
 - of miosis, 379
 - of ocular pigmentation, 377–378
 - of refraction, 377

- Electroretinography (*cont.*)
 of sex, 377
 of vitreous hemorrhage, 379
 of vitreous substitute, 379–380
 electrodes, 177–180
 first published human electroretinogram, 6–7
 five basic responses, diagram of, 284
 flash illumination in, 372
 flicker, 348–351
 focal, 334–338
 in cataract, 336–337
 cone amplitude, 335
 in macular holes, 337
 in maculopathy, 336
 normal values, 335
 stimulation, 373
 uses, clinical, 335–337
 in fundus albipunctatus, 718, 733–734
 history of, 5–13
 early discoveries, 5–13
 I-ERG analysis, 7
 implicit times, 289–290
 in infant, 410
 intensity series, 353, 355, 357
 intersession variability, 380–381
 latencies, distribution of, 289–290
 light adaptation in, 375
 light calibration in, 373–374
 light stimulation in, 371–376
 equipment and procedure for, 329–332
 in lipofuscinosis, neuronal ceroid, 788
 measurements, standards for, 287–288
 monitoring
 in intensive care unit, 607–610
 intraoperative, 607–610
 of Müller cell responses, 103
 negative response
 near rod threshold, 352
 threshold, 353
 in night blindness (*see* Night blindness, congenital stationary, incomplete-type, electroretinography in)
 normal
 with negative ERGs, 532
 values, 287
 variation, 376–378
 ocular media changes in, 379–381
 origins
 anatomy, 89
 determination methods, 88–89
 intracellular recordings, 88
 ion recordings, 88–89
 pharmacology, 89
 in parkinsonism, 811–812
 pattern, 291–300
 age and, 294
 in Alzheimer's disease, 795
 amplitude, 291–292
 color in, 298
 contrast component, 296–298
 defocus, 294
 electrodes, 292–294
 electrodes, corneal position, 293
 electrodes, penetrating microelectrodes, 295
 electrodes, reference position, 293–294
 evaluation of, 291–292
 in glaucoma, 549–556, 766–772
 hints on useful clinical technique, 293
 latency, 292
 in Leber's hereditary optic atrophy, 764
 luminance of, 296–298
 in multiple sclerosis, 800
 normal, 292, 294
 in ocular hypertension, 550, 766–772
 in optic nerve function, 549–556
 origin, 294–295
 pupil size, 294
 recording, practical problems in recording reliable clinical results, 292–294
 recording, "steady-state," 292
 recording, "transient," 291–292
 research for, clinical and animal, 294–295
 spatial frequency, 295–296
 stimulus parameters, 295–298
 two fractions of, demonstration of, 297
 pigment epithelium responses, slow, 328–329
 preparation of patient, 287
 fixation, 287
 pre-exposure to light, 287
 properties of, summary of, 7
 protocol, 287–288
 recording
 corneal dc, direct, 330
 dc, 329
 early, 5–6
 by Einthoven and Jolly in 1908, 6
 equipment for, 329–332
 with long time constant, 323–324
 procedure, 329–332
 protocols, 328–333
 with short time constant, 325
 standards for, 287–288
 in Refsum's disease, 507
 relation to PI, PII, and PIII, 7
 reporting of, 287–288
 responses, 288
 flicker, 288
 maximal, 288
 oscillatory potentials and, 288
 "rod," 288
 single-flash "cone," 288
 to various wavelengths of light, 11
 in retinal artery occlusion, 617–618
 in retinal vein occlusion (*see* Retina, vein occlusion, central, electroretinography)
 in retinitis pigmentosa (*see* Retinitis pigmentosa, electroretinography in)
 X-linked recessive female carrier, heterozygote, detection, 741–743
 in retinoschisis, X-linked juvenile, 728
 rod, dark adaptation of, 394–395
 scotopic threshold response, 122, 352–362
 signal processing, 331
 standards for, 283–288
 stimulation for, local, 215
 stimulators for, 224–226
 subject preparation for, 374–375
 technical issues in, 371–383
 technology, basic, 285–287
 in thioridazine retinopathy, 603
 of vessels in ischemia, 613–618
 in vitamin A deficiency, 738
 waveform
 changes characteristic of disease, 488–491
 "negative," disorders with, 489
 Embryological origins, 53–55
 EOG (*see* Electro-oculography)
 Epithelium (*see* Pigment epithelium)
 Equipment
 electronic recording, standard in ERG, 287
 for electrophysiological testing, 175–228
 for ERG recording, 329–332
 monitoring, 193–204
 ERG (*see* Electroretinography)
 ERP (*see* Early receptor potential)
 Evoked potential(s)
 in Alzheimer's disease, 793–796
 topographical (*see* Mapping topographical evoked potential)
 visual (*see* Visual evoked potential)
 e-wave, 115
 Eye
 (*See also* Ocular movements artifacts, 388–389 in electro-oculography, 302–303 neuritis, 800)
- ## F
- Fast-oscillation trough, 95–96
 intraretinal recordings during, 95
 Feedback loops: in retina, 45–47
 Filter(s)
 analog, 186–187
 band-pass, 186
 band-pass, computer program for, 205–206
 band-pass, digital, 205–210
 comparisons with other filters, 206–207
 testing hints, 207
 band-reject, 186

- BP-FIR, 206
 color stimuli, 216–217
 digital, 186–187
 high-pass, 186
 low-pass, 186, 206
 smoothing, digital, 206–207
 3-dB, 207
- Filtering
 calibration of delays due to, 195
 phase-free, 243
 technique in oscillatory potential recording, 322
- Flash
 illumination in
 electroretinography, 372
 luminance (*see* Luminance, flash)
 response in diabetes, 320
 stimulator, voltage drive circuit of, 223
 visual evoked cortical potential in
 developmental delay, 585–588
 visual evoked potential (*see* Visual evoked potential, flash)
 visual evoked response (*see* Visual evoked response, flash)
- Flicker, 465–466
 electroretinography, 348–351
 implicit time in diabetic retinopathy, 623
 responses, 349
- Fluorescein (*see* Angiography, fluorescein)
- Fluorescence
 light micrograph of cone matrix sheath, 62
 microscopy of retinal radial section (in dogfish), 79
- Focal electroretinography (*see* electroretinography, focal)
- Fourier analysis, 237–243
 checkerboards and, 244–246
 domains, 240–241
 practical considerations on using, 241–243
 spatial, 243–246
 linearity, 243
 receptive fields, 246
 spatial frequency, 244
 time vs. space, 243–244
 square wave (*see* Square wave)
- standard periodic signals, 238
 test signals, 240
- Fourier integral, 238–240
- Fourier, Joseph, 237
- Fourier spectrum: of periodic impulses, 239
- Fovea
 atrophy
 centralis, in cone dystrophy, 540
 after chloroquine, 595
 development of, 56
 light micrograph of (in monkey), 57
 midget pathways in, 43–44
 neural connections in, 44
 neuropil, electron micrograph of, 35
 radial section through, 28
- Full-field dome, 372
- Fundus
 abnormalities in night blindness, congenital stationary, 715–719
 albipunctatus, 717–719, 730–736
 clinical findings, 730–732
 dark adaptation in, 718
 dark adaptation curves from, 733
 electro-oculography in, 734–735
 electroretinography in, 718, 733–734
 psychophysical test results in, 732
 reflectometry in, fundus, 732–733
 visual pigment regeneration in, 733
 in Best's disease, 693
 in chorioretinitis, birdshot, 641
 in diabetic retinopathy, 625, 626, 628, 629, 631, 632
 dystrophy, Sorsby's, 705
 flavimaculatus (*See also* Stargardt's disease)
 advanced, 677
 case studies, 676–681
 diagnosis, differential, 676
 electrophysiological findings in, 681
 -like diseases, 675–682
 -like diseases, differential diagnosis, 675–682
 -like diseases, splitting vs. lumping, 675–682
 in Leber's hereditary optic atrophy, 763
 in night blindness, incomplete-type, 722
 reflectometry, 264–267
 in Stargardt's disease, 670–671
- ## G
- Gain
 of amplifiers, 185
 calibration of, 194–195
- Ganglion cell
 firing of (in cat), 82
 on/off, action potentials from, 367
 properties of, summary of (in cat), 83
 types in retina (in monkey), 37
- Ganzfeld
 dome, 372
 electro-oculography in
 cone dystrophy, X-linked, 759
 electroretinography in
 Bietti's crystalline dystrophy, 688
 in cone dystrophy, X-linked, 758
- fields
 relationship to b-wave amplitude reduction, 393
 relationship to cone b-wave implicit time, 393
 rod b-wave amplitude change in dark after, 394
 stimulation, 214–215, 332
 stimulator, 371–372
- Gaussian noise, 247
- Gender
 difference in P100 peak latency, 420
 in retinitis pigmentosa, 516
- Genetic carriers: rapid off-response in, 344
- Genetics
 hereditary forms of cone dysfunction, 537
 hereditary transmission of night blindness, incomplete-type, 724
 inheritance
 in Leber's hereditary optic atrophy, 763
 pattern in retinitis pigmentosa, 516, 517
 of Stargardt's disease, 669
 inherited drusen, 668
 molecular, of gyrate atrophy, 655–656
- Genotype: in albinism, 774
- Geometric relationships
 in extended primary and secondary sources, 199
 with point source, 198
- Glaucoma
 chronic open-angle, diagnosis, 767
 electroretinography in, pattern, 549–556, 766–772
- Glial cell
 K⁺ spatial buffer process in, 88
 of retina, 38–39
- Glioma: optic nerve, surgery of, flash VEP during, 609
- Global field power, 268
- Glutamate: depolarization of rod horizontal cell by pulses of, 81
- L-Glutamate: conductance changes mediated by, 79–81
- Gold foil lid-hook electrodes, 179
- Goldmann
 perimetry in gyrate atrophy, 653
 visual fields, for Bietti's crystalline dystrophy, 685, 686, 687
- Goldmann-Weekers dark adaptometry: in cone dystrophy, X-linked, 759
- Grating(s), 465–466
 acuity
 in infant, 408–409
 tests, 462
 sinusoidal, 466
 stimuli, comparison with checkerboard stimuli, 409
- Ground loop, 386
- Gunshot wound: orbit in, 569
- ## H
- Halothane:
 electroretinography of children under, 378
- Handicapped patients: visual acuity of
 multihandicapped patients, 463
- Head injury, 570
- Hemianopia
 bitemporal, 558

- Hemianopia (*cont.*)
 macular-sparing,
 homonymous, 560,
 561
- Hemisphere: responses to
 two spatial
 frequencies, 149
- Hemorrhage: vitreous, effect
 on
 electroretinography,
 379
- Histograms
 log (bp/bs), 529–530
 of photopic ERG
 amplitudes, 290
- History
 of electro-oculography,
 14–16
 of electroretinography,
 5–13
 of visual
 electrophysiology,
 1–22
 of visual evoked cortical
 testing, 17–22
- Hormones: and visual
 nervous system,
 169–170
- Hydroxychloroquine: causing
 retinal toxicity,
 594–599
- Hyperosmolarity responses,
 163–166
- Hypertension: ocular,
 pattern
 electroretinography in,
 550, 766–772
- Hypopigmentation: in
 chloroquine toxicity,
 595
- Hysteria: electrodiagnostic
 testing in, 573–577
- I**
- I-ERG analysis, 7
- Illuminance
 measurement problems,
 200–202
 of red flickering test
 stimulus, 470
 retinal, 201
 of sinusoidally flickered
 test stimulus, 470
 units, conversion factors
 for, 199
- Illumination
 background
 effect on cone
 electroretinography,
 392–394
 in electroretinography,
 372
 results of, 392
- flash, in
 electroretinography,
 372
- Impedance
 electrode, measurement of,
 194
 source, measurement of,
 193
- Infant
 electroretinography in, 410
 high visual evoked
 potential sensitivity,
 clinical implications of,
 414–415
 management for testing,
 279–280
 stereopsis in, 410
 vernier acuity in, 409–410
 visual acuity estimation by
 visual evoked cortical
 potentials, 408–416
 contrast sensitivity, 409
 measurement methods,
 410–412
 philosophy of, 408
 visual evoked potential
 latency, 410–411
 steady-state, 411
 sweep technique,
 411–412
 transient, 410
 visual performance tasks,
 408–410
- Inflammatory states:
 electrophysiological
 evaluation, 611–645
- Inheritance (*see* Genetics,
 inheritance)
- Instrumentation: for rod and
 cone perimetry, 476
- Intensity relations, 260–263
 significance of, 260–263
- Intensive care unit:
 monitoring with visual
 evoked potentials and
 ERG, 607–610
- International ten-twenty
 system, 400
- Interphotoreceptor
 matrix
 composition, 57–63
 embryological origins,
 53–55
 function, 57–63
 morphology, 57–63
 relationships in central
 retina, light
 micrograph of (in
 monkey), 54
 structure, 61–63
 space, development of,
 56–57
- Interplexiform cell: in retina
 (in cat), 46
- Intraocular pressure:
 elevation, scotopic
 threshold response in,
 360
- Intraoperative monitoring:
 with visual evoked
 potentials and ERG,
 607–610
- Ion
 channels, Müller cell,
 106–107
 movements across surface
 membrane of rod, 70
 recordings in
 electroretinography
 origins, 88–89
- Iron chelators: and retina,
 159
- Ischemia: vascular,
 electroretinographic
 ratios in, 613–618
- Ischemic optic neuropathy,
 636–639
- Isodensity maps: of cone
 photoreceptor density,
 49
- J**
- Jansky-Bielchowsky
 lipofuscinosis,
 786–789
- Juvenile (*see* Children)
- K**
- K^+ changes: source of, and
 b-wave generation,
 105
- K^+ concentration:
 extracellular,
 light-evoked
 variations, 105
- K^+ conductance, 105–106
 distribution over Müller
 cells, 106
- K^+ /Müller cell hypothesis
 (*see* Müller cell/ K^+
 hypothesis)
- K^+ -Müller cell mechanism:
 for scotopic threshold
 response, 122–123
- K^+ spatial
 buffer process in glial cell,
 88
 buffering, 87–88
- K^+ variations: in b-wave
 generation, 104–105
- Kernel
 analysis, 254–259
 linear approximations of
 nonlinear system, 256
 stimuli for, 256–258
 first-order, 255–256
- second-order, 255, 256
 systems, 255–256
- Kufs lipofuscinosis, 789
- L**
- Lake-Cavanagh
 lipofuscinosis,
 787–789
- Lamp, xenon flash, 213
 time course of light output
 from, 214
- L-dopa: and visual nervous
 system, 168
- Leber's hereditary optic
 atrophy, 763–765
 associated neurological
 findings, 764
 color vision in, 763
 diagnosis, differential, 764
 electrophysiology, 764
 electroretinography in,
 pattern, 764
 fundus in, 763
 inheritance, 763
 in Japan, 764
 pathogenesis, 764
 retinal function in,
 763–764
 treatment, 764
 visual acuity in, 763
 visual evoked cortical
 potentials in, 764
 visual fields in, 763–764
- Lens (*see* Contact lens)
- L-glutamate: conductance
 changes mediated by,
 79–80
- Light
 adaptation, 73–75
 cone electroretinography
 growth during,
 391–392
 early receptor potential
 and, 318–319
 in electroretinography,
 375
 adjustment, standard in
 ERG, 286
 background calibration,
 standard in ERG, 286
 background illumination,
 standard in ERG, 286
 background intensity,
 standard in ERG, 286
 calibration in
 electroretinography,
 373–374
 standard, 286
 concentration in
 light-emitting diodes,
 222
 diffusion, standard in
 ERG, 285

- electrical changes
 produced by, 69–72
 emitting diodes, 221–227
 applications, 224
 arrays, 224
 connections of, series
 and parallel, 224
 construction of, 222
 feedback loop of current
 drive to enhance, 223
 light concentration in, 222
 relationship between
 current and light
 output, 223
 measurement (*see*
 Photometry)
 micrograph
 fluorescence, of cone
 matrix sheath, 62
 of fovea (in monkey), 57
 of interplexiform cell in
 retina (in cat), 46
 of midjet bipolar cell, 33
 of Müller cells in retina
 (in monkey), 38
 of peanut
 agglutinin-binding
 molecules (in
 monkey), 58
 of relationships in
 central retina (in
 monkey), 54
 peak, 96–97, 546–547
 in electro-oculography,
 303–305
 recalibration standard in
 ERG, 286
 sensitivity of postsynaptic
 cells, 80–81
 sources, standard in ERG,
 285–286
 stimulation in
 electroretinography,
 371–376
 stimulus
 adjustment, standard in
 ERG, 286
 calibration in ERG, 286
 duration, standard in
 ERG, 285–286
 strength, standard in
 ERG, 286
 wavelength, standard in
 ERG, 286
 Linear approximations: of
 nonlinear system, 256
 Linearity: of amplifiers, 185
 Lipofuscinosis
 Jansky-Bielchowsky,
 786–789
 Kufs, 789
 Lake-Cavanagh, 787–789
 neuronal ceroid, 786–792
 adult, 789
 animal models, 790
 atypical forms, 789
 b-wave in, 790
 clinical findings,
 786–789
 electrophysiology,
 786–789
 findings in
 heterozygotes,
 789–790
 infantile, 786
 infantile, late, 786–787
 juvenile, 788–789
 juvenile, cataract in, 788
 juvenile, early, 787–789
 juvenile, early,
 electroretinography in,
 788
 juvenile, electron
 microscopy in, 789
 prenatal diagnosis,
 789–790
 treatments,
 experimental, 790
 types, tabular data, 787
 ultrastructure in, 789
 Santavuori-Haltia, 786
 Stengel-Spielmeyer-Vogt,
 788–789
 Log (bp/bs)
 histograms, 529–530
 in retinitis pigmentosa,
 528–530
 Loop: ground, 386
 Luminance, 201
 along elements of
 checkerboard, 245
 in ERG, pattern, 296–298
 flash
 in albinism, 432
 calibration with
 subjective photometer,
 202
 illuminance (*see*
 Illuminance)
 measurement problems,
 200–202
 of square-wave flickering
 test probe, 471
 units of, conversion table,
 200
 visual acuity as function
 of, 460
 in visual acuity testing,
 459–460
- ## M
- Macula
 in cone dystrophy, 540
 X-linked recessive, 757
 degeneration with
 nyctalopia, 679
 edema, 496–497, 524
 holes: focal ERG in, 337
 normal, in night blindness,
 incomplete-type, 724
 in retinitis pigmentosa,
 523, 524
 schisis vs. edema,
 fluorescein
 angiography in,
 496–497
 Maculopathy
 angiography of,
 fluorescein, 672
 focal ERG in, 336
 Magnetic fields: in
 environment,
 phosphene related,
 364–365
 Magnetically evoked retinal
 responses, 363–368
 Magnetophosphenes
 comparison with
 electrophosphenes,
 365–366
 generation of, possible site
 of, 366–367
 sensitivity maxima,
 363–364
 threshold values, 364, 365,
 366
 thresholds of, 363–364
 Mains
 hum reduction and
 double-sided
 amplifiers, 386–387
 interference
 entering recording
 situation, 385
 theory of, 385–386
 Malinger:ing:
 electrodiagnostic
 testing in, 573–577
 Management of patient,
 277–280
 children, 279–280
 infants, 279–280
 Mapping topographical
 evoked potential
 component latency, 268
 global field power, 268
 potential map series, 273
 potential profiles
 enhanced display of, 272
 series of, 271
 topographical potential
 profile construction,
 270
 Melanoma, malignant,
 643–645
 electro-oculography in,
 644–645
 Membrane potential
 rod, 77
 transmitter release control
 by, 76–77
 Memoir: personal, 3–4
 Mesoridazine, 604
 Microelectrodes, 8–9
 Micrograph
 electron (*see* Electron
 micrograph)
 light (*see* Light micrograph)
 Microscopy
 electron, in neuronal
 ceroid lipofuscinosis,
 juvenile, 789
 fluorescence, of retinal
 radial section (in
 dogfish), 79
 Minimum-phase rule: in
 signal analysis,
 234–235
 Miosis: effect on
 electroretinography,
 379
 Model(s)
 in lipofuscinosis, neuronal
 ceroid, animal, 790
 mathematical, in
 electro-oculography,
 305–306
 Molecular genetics: of gyrate
 atrophy, 655–656
 Monitoring
 equipment, 193–204
 ERG (*see*
 Electroretinography,
 monitoring)
 eye position with
 electro-oculography,
 303
 of intensive care unit with
 visual evoked
 potentials and ERG,
 607–610
 intraoperative, with visual
 evoked potentials and
 ERG, 607–610
 for retinal toxicity,
 596–598
 Monoamines: retinal effects
 of, 156–157
 Monochromatism: blue cone,
 753–755
 Monocular
 acuity measurement, 413
 latency variation, mean,
 normal values, 438
 Monosodium aspartate: and
 ERG intensity series,
 357
 Mucopolysaccharidosis VI,
 63–64
 Müller cell
 cytology, 61
 electroretinographic
 component, 92–93
 electroretinography of, 103
 function, 61

- Müller cell (*cont.*)
 intracellular responses, 103
 ion channels, 106–107
 K⁺ conductance
 distribution over, 106
 /K⁺ hypothesis
 challenges of, 107–108
 summary of, 107
 membrane properties,
 105–107
 origin of b-wave (*see*
 b-wave, Müller cell
 origin of)
 of retina (in monkey), 38
 Multiple sclerosis, 797–805
 color sense abnormality in,
 807–808
 electroretinography in,
 pattern, 800
 with optic nerve
 demyelination, 552
 paraplegia due to,
 progressive spastic,
 799
 P100 and, 807–808
 PVEP in, abnormal,
 incidence of, 798
 visual acuity decrease in,
 806–807
 visual dysfunction in,
 806–809
 visual evoked cortical
 potential in
 delayed, 806–809
 pattern, 806–810
 pattern, delayed,
 underlying
 mechanism, 809
 visual evoked potentials
 in, flash, 799
 visual field defects in,
 808–809
- Muscle
 artifacts, 388–389
 biopsy in gyrate atrophy,
 655
- M-wave, 118–120
 generation, summary of
 events underlying, 116
- ## N
- Nerve(s)
 connections in fovea, 44
 optic (*see* Optic nerve)
 organization of retina,
 25–52
- Nervous system
 central, dysfunction,
 761–813
 visual
 anesthetics and, 169
 anticholinergics and, 169
 antiepileptics and, 169
 cholinergics and, 169
 drugs of abuse and, 170
 hormones and, 169–170
 L-dopa and, 168
 neuropsychiatric drug
 effects on, 167–173
 tranquilizers and, minor,
 169
- Neural (*see* Nerve)
- Neuritis
 of eye, 800
 optic, 807
 retrobulbar, 553, 554
- Neuromodulators: in retina,
 48
- Neuron(s)
 intracellular responses
 from, and oscillatory
 potentials, 126–128
 in rod pathways through
 retina, 40
- Neuronal ceroid
 lipofuscinosis (*see*
 Lipofuscinosis,
 neuronal ceroid)
- Neuropathy: optic, ischemic,
 636–639
- Neuropeptides: in retina, 48
- Neuropharmacology:
 experimental, of
 retina, 153–157
- Neuropil: of fovea, electron
 micrograph of, 35
- Neuropsychiatric drugs:
 effects on visual
 nervous system,
 167–173
- Neurotransmitters: in retina,
 47–50, 83–84
- Night blindness, 521
 congenital stationary,
 713–720
 with abnormal fundi,
 715–719
 carrier state of, 711–712
 congenital stationary,
 incomplete-type,
 721–725
 angiography in,
 fluorescein, 722, 724
 clinical findings,
 721–724
 dark adaptation in,
 psychophysical, 721
 diagnosis, differential,
 724–725
 electro-oculography in,
 722
 electroretinography in,
 723
 electroretinography in,
 photopic, 722
 electroretinography in,
 scotopic, 722
 electroretinography,
 single-bright-flash, 722
 fundus in, 722
 hereditary transmission,
 724
 macula in, normal, 724
 refractive error in,
 721–722
 visual acuity in, 721, 724
 visual field in, 721
 congenital stationary, with
 normal fundi, 713–715
 congenital stationary,
 X-linked recessive, 711
 dark adaptation curve in,
 454
 rod-cone interaction and,
 suppressive, 471–472
- Noise
 analytic techniques and,
 246–249
 electronic sources, 184
 Gaussian, 247
 physiological, and visual
 signals, 184
 signal-noise ratio
 improvement with
 averaging, 249–250
- Nonlinear system: linear
 approximations of, 256
- Nonphotic standing potential
 responses, 163–166
- NP207 (*see* Thioridazine,
 NP207 and)
- Nucleotide, cyclic
 cascade, 72–73
 retina and, 154–155
- NVI, 614, 615
- Nyctalopia
 with macular
 degeneration, 679
 in retinitis pigmentosa,
 520–521
- ## O
- Ocular
 (*See also* Eye)
 hypertension, pattern
 electroretinography in,
 550, 766–772
 media changes in
 electroretinography,
 379–381
 pigmentation, effect of, in
 electroretinography,
 377–378
 trauma, evaluation,
 opaque media,
 567–572
- Off-response: rapid (*see*
 Rapid off-response)
- Oguchi's disease, 715–717
 dark adaptation curve, 716
- Ophthalmoscope: hand-held,
 dual-beam,
 maxwellian-view
 stimulator, 373
- Optic
 atrophy
 with disc telangiectasia,
 499
 of Leber (*see* Leber's
 hereditary optic
 atrophy)
 temporal, in cone
 degeneration, 541
 temporal, and retinitis
 pigmentosa, 521–524
- nerve
 damage, 571
 demyelination with
 multiple sclerosis, 552
 demyelination, pattern
 electroretinography in,
 551–552
 disease and early
 receptor potential, 320
 dysfunction, 761–813
 dysfunction, pattern
 electroretinography in,
 550–553
 function, pattern
 electroretinography in,
 549–556
 glioma surgery, flash
 VEP during, 609
 pallor, 522
 pallor after chloroquine,
 595
 response, and
 beta-adrenergic
 agents, 156
 stimulation, retinal
 potentials evoked by,
 129
 neuritis, 807
 neuropathy, ischemic,
 636–639
- Optotype tests, 460–462
- Orbit: in gunshot wound, 569
- Ornithine: metabolism,
 biochemical pathways
 in, 655
- Oscillations
 fast, 546–547
 slow, 546–547
- Oscillatory potentials,
 125–128
 amplitude measurements,
 327
 calculated energy of, 324,
 326
 cells generating, 125–126
 depth profile in retina (in
 animals), 126
 in diabetic retinopathy,
 620–622

- drugs affecting, 168
energy density spectrum, 323
ERG responses and, 288
intracellular responses from neurons and, 126–128
normal, 325–327
origin of, 125
recording, 322–327
 adaptational conditions, 324–325
 filtering technique, 322
 with short time constant, 325
 stimulus light, 322–324
- P**
- Paraplegia, spastic
 progressive
 electroretinography in, 811–812
 multiple sclerosis causing, 799
- Parkinsonism, 811–813
 electroretinography in, 811–812
 psychophysics in, 812
 visual evoked potentials in, 811
- Pattern
 dystrophy (*see* Dystrophy, pattern)
 electroretinography (*see* Electroretinography, pattern)
 visual evoked potentials (*see* Visual evoked potentials, pattern)
- Peanut agglutinin-binding molecules, 58
- Pediatric (*see* Children)
- Pedigree
 in albinism, 777, 778
 in blue cone monochromatism, 754
 in X-linked retinoschisis, 750
- Perimetry
 Goldmann, in atrophy, gyrate, 653
 rod and cone, 475–482
 analyses, 475–482
 computerized testing, 475–482
 data processing steps, 477
 instrumentation for, 476
- Pharmacologic effects: in retinal electrophysiology, 151–162
- Pharmacology
 of retina (*see* Retina, pharmacology of)
 of scotopic threshold response, 357–358
- Phenothiazine
 chemical structure, 601
 retinal toxicity of, 600–606
- Phenotype: in albinism, 774
- Phosphene-related magnetic fields: in environment, 364–365
- Phosphodiesterase inhibitors: and retina, 154–155
- Phosphors: typical screen, for cathode ray tubes, 218
- Photometry, 195–200
 digital, for flash calibration, 202
 measures and their relationships, 198
 subjective, calibration of flash luminance with, 202
 units, common, 197–200
- Photopic/scotopic equivalence, 202–203
- Photoreceptors, 28–31
 cells
 cytology, 59–61
 development of, 55–57
 function, 59–61
 -pathologies, 64
 density
 cone, isodensity maps of, 49
 cone and rod, 49
 interphotoreceptor (*see* Interphotoreceptor)
 mediation, 478, 480, 481
 -retinal pigmented epithelium interface, 53–68
- Phototransduction
 cGMP cascade of, 74
 in rods and cones, 69–75
- Pigment
 deposition in retinitis pigmentosa, 521
 epithelium
 diseases of, c-wave in, 545–546
 responses, slow, in electroretinography, 328–329
 epithelium, retinal
 cell cytology and function, 59
 characteristics of responses, 164
 in chloroquine toxicity, 595
 composition, 57–63
 development of, 56
 diseases, 647–706
 electroretinographic component, 93–95
 embryological origins, 53–55
 function, 57–63
 morphology, 57–63
 pathologies, 63–64
 with pattern dystrophy, 497
 -photoreceptor interface, 53–68
 relationships in central retina, light micrograph of (in monkey), 54
 and visual system testing, 486–487
 visual, regeneration in fundus albipunctatus, 733
- Pigmentation
 in dystrophy, pattern, 703
 ocular, effect of, in electroretinography, 377–378
- Pituitary syndromes, 783–785
 diagnostic aspects, 783
 electrophysiology in, 783–785
- Plexiform layer
 inner, 34–37
 outer, 32–34
- PI: relationship to electroretinography, 7
- P100
 latency in developmental delay, 583
 multiple sclerosis and, 807–808
 peak latency and age, 420
 gender differences in, 420
 topographical distribution, 436
- Postsynaptic cell
 circuit of, equivalent, 81
 light sensitivity of, 80–81
 synaptic gain of, 80–81
 responses, 77–79
- Potential(s)
 evoked (*see* Evoked potentials)
 membrane (*see* Membrane potential)
 nonphotic standing potential responses, 163–166
 oscillatory (*see* Oscillatory potentials)
 receptor (*see* Receptor potentials)
 retina (*see* Retina, potentials)
- Prader-Willi syndrome, 781
- Preamplifiers, 183–185
- Prematurity, 586, 587
- Prenatal diagnosis: of neuronal ceroid lipofuscinosis, 789–790
- Protan(s)
 carriers, spectral sensitivity of rapid off-response in, 343
 patients, early receptor potential in, 344–346
 rapid off-response in, 339–344
- Proximal negative response, 115–116, 119
 generation, summary of events underlying, 116
- Pseudo-Foster-Kennedy syndrome, 638
- Psychiatric conditions: drugs for, 167–168
- Psychophysical
 techniques relevant to electrophysiological testing, 445
 test results in fundus albipunctatus, 732
 testing, 443–482, 445–458
- Psychophysics
 of drusen, dominant, 665–668
 light-emitting diodes in (*see* Light-emitting diodes)
 in parkinsonism, 812
- PIII
 proximal, 99–100
 relationship to electroretinography, 7
 slow, electroretinographic component, 92–93
- PII
 relationship to electroretinography, 7
 scotopic threshold response waveform interaction with, 355
- Pupil
 area vs. contrast threshold, 422
 diameters, 201
 dilatation for ERG, 287
 size
 aging and, 423
 in pattern electroretinography, 294

Pyridoxine-responsive gyrate atrophy, 650–651, 652

R

Radiation: visible, sources of, 212

Rapid off-response
amplitude in normal subjects, 341
in deuterans, 339–344
in genetic carriers, 344
in protans, 339–344
mean sensitivity of, 343
relationship to early receptor potential, 346
sensitivity of
log ratio of, 341, 342
spectral, 340
spectral, in protan carriers, 343

RCS rat, 63

Receptor potential, early, 317–321, 488
amplitude
log ratio of, 345
mean and standard deviation, 345
applications, clinical, 317–321
in color blindness, 319
cone dystrophy in, 319
disease and, 319–320
in duetan patients, 344–346
light adaptation in normal response, 318–319
nature of, 317–318
optic nerve disease and, 320
origin of, 317–318
in protan patients, 344–346
relationship to rapid off-response, 346
retinal disease and, 320
in retinitis pigmentosa, 319–320
spectral sensitivity curve of, 344

Receptor potential: late, 318

Reflectometry, fundus, 264–267
in fundus albipunctatus, 732–733

Refraction

effect of, in electroretinography, 377

error in night blindness, incomplete-type, 721–722

linear regression of b-wave amplitude on, 378

Refsum's disease:

electroretinography in, 507

Reticular dystrophy, 701

Retina

artery occlusion, 532–533
central, 545

electroretinography in, 617–618

astrocyte in (in cat), 39

atrophy, gyrate (*see* Atrophy, gyrate, of choroid and retina)

beta-adrenergic mechanisms in, 155–156

Bietti's dystrophy (*see* Bietti's crystalline dystrophy of cornea and retina)

cell(s)

amacrine (in monkey), 36

biology, principles of, 23–84

bipolar, 32

bipolar, receptive field of, center-surround organization, 80

ganglion (*see* Ganglion cell)

glial (*see* Glial cell)

horizontal, 34

interplexiform (in cat), 46

midget, light micrograph of, 33

Müller (*see* Müller cell)

circuits, scheme of, 152

composition, 57–63

cone (*see* Cone of retina)

damage, inner, a-wave and b-wave in, 534

dark-adapted responses in, amplitudes of, 122, 123

-degenerative mice, 64

development of, 53–55

disease
early receptor potential and, 320

hereditary, with distinctive fluorescein angiography, 494–500

effects

of adenosine on, 156–157

of monoamines on, 156–157

electrophysiology

drugs and (*see* Drugs and retinal electrophysiology)

pharmacological effects in, 151–162

electroretinographic

components arising in (*see* Electroretinography, components arising in retina)

embryological origins, 53–55

facts and figures

concerning, 48

feedback loops in, 45–47

function, 57–63

in Leber's hereditary

optic atrophy, 763–764

in Sorsby's fundus

dystrophy, 705

gain in scotopic threshold response, 358–359

illuminance, 201

image size, calculation of, 203

inner signals in, 81–83

iron chelators and, 159

magnetically evoked responses, 363–368

midretina, diseases, 707–760

morphology, 57–63

neural organization of, 25–52

neuromodulators in, 48

neuropeptides in, 48

neuropharmacology, experimental, 153–157

neurotransmitters in, 47–50, 83–84

nucleotides and, cyclic, 154–155

in origins of scotopic threshold response, 356–357

outer, diseases, 707–760

pharmacology of, 157–160

topical application, 157–158

phosphodiesterase inhibitors and, 154–155

physiological mechanisms, 145–176

physiology, 69–84

pigment epithelium (*see* Pigment epithelium, retinal)

potentials
evoked by electrical current, transretinal, 129–130

evoked by optic nerve stimulation, 129

extracellular, responses not evoked by light, 129–131

radial section of, 27

fluorescence microscopy of (in dogfish), 79

retinoids and, 158–159

rods (*see* Rods of retina)

toxicity (*see* Toxicity, retinal)

vein occlusion, 533–536

branch, 617

vein occlusion, central, 568

electroretinographic

amplitudes, 613–615

electroretinographic

ratios in, 613–617

intensity-response

analysis, 616–617

temporal factors, 615–616

vessel

after chloroquine, 595

disease, b/a-wave

amplitude ratios in, 531–536

vinca alkaloids and, 159–160

Retinitis pigmentosa, 501–530

age of onset and duration, 519–520

clinical characteristics, 515

cone-rod degenerations in, 510–527

course, 501–509

natural, of common

forms, 504–506

dark adaptation in, 520

diagnosis, differential, 512–513

early receptor potential in, 319–320

electrophysiological parameters vs. clinical findings, 510–527

electroretinography in, 516–519

for early detection, 501–503

full-field, computer-averaged, 504

full-field responses, 502, 503

specialized recording techniques, 503–504

gender in, 516

historical background, 511–512

inheritance pattern, 516, 517

inversa

adult-onset, 678

juvenile-onset, 677

log (bp/bs) in, 528–530

macula in, 523, 524

- nyctalopia in, 520–521
 optic atrophy and,
 temporal, 521–524
 patients and methods,
 513–515
 pigment deposition in, 521
 rare treatable forms,
 506–507
 results, 515–524
 retinal pigment epithelial,
 preserved
 para-arteriolar, 497
 scatterplots in, 519, 520
 sector, 497
 signs and symptoms, 501
 simplex, Coats's reaction
 in, 499
 visual acuity in, 520
 visual function change in,
 505–506
 X-linked, 504
 recessive, female
 carriers, ERG
 detection, 741–743
 Retinitis punctata albescens:
 atypical, 678
 Retinoids: and retina,
 158–159
 Retinopathy
 diabetic, 619–635
 angiography in,
 fluorescein, 626, 628,
 629, 632
 b-wave in, scotopic,
 622–623
 case examples, 625–634
 DRS-HRC, 621, 622
 electro-oculography in
 625
 electroretinography in,
 620–625
 electroretinography in,
 progression
 prediction, 621–622
 electroretinography in,
 protocol, 624–625
 electroretinography in,
 severity, 620–621
 electroretinography in,
 temporal aspects, 623
 flicker implicit time in,
 623
 fundus in, 625, 626, 628,
 629, 631, 632
 high-risk characteristics,
 622
 oscillatory potentials in,
 620–622
 VECPs in, 625
 thioridazine (*see*
 Thioridazine
 retinopathy)
 Retinoschisis
 reticular peripheral, 727
 X-linked, carrier state
 detection, 748–752
 method, 748–750
 results, 750–751
 X-linked juvenile, 496,
 726–729
 dark adaptation in, 728
 electroretinography in,
 728
 macula in, 727
 X-linked, pedigrees, 750
 X-linked, rod-cone
 interactions in, 750
 Retrobulbar neuritis, 553, 554
 Retrochiasmal lesions,
 560–562
 bilateral dysfunction, 562
 unilateral dysfunction,
 560–562
 Rhodopsin: in vitamin A
 deficiency, 739
 Riggs contact lens electrode,
 10
 Ring scotoma, 518
 Rod(s)
 -cone
 degenerations in retinitis
 pigmentosa, 510–527
 dystrophy, 512
 dystrophy, atypical, 679
 dystrophy, progressive,
 variation, 678
 interaction in normal
 subjects, 749
 interaction in
 retinoschisis, X-linked
 carriers, 750
 -cone interaction,
 suppressive, 469–474
 background, 469–470
 clinical perspective,
 470–471
 color vision disorders
 and, 472
 newer developments,
 472–473
 night blindness and,
 471–472
 X-linked inherited
 conditions and, 472
 -cone sensitivity loss maps,
 480, 481
 electroretinography, dark
 adaptation of, 394–395
 membrane potential, 77
 pathway in starlight and
 scotopic threshold
 response, 358
 perimetry (*see* Perimetry,
 rod and cone)
 of retina
 cells, horizontal,
 depolarization by
 glutamate, 81
 cells, responses of, 78
 circulating current
 reduction through,
 produced by light
 flashes (in monkey),
 71
 degeneration,
 progressive, 64
 desensitization of (in
 monkey), 75
 electron micrograph of
 (in monkey), 29
 functional
 interconnections of,
 75–76
 ion movements across
 surface membrane of,
 70
 pathways, neurons in,
 40
 photocurrent
 fluctuations of, 73
 photoreceptor density,
 49
 photoresponse spectral
 sensitivity of (in
 monkey), 72
 phototransduction in,
 69–75
 rod-cone coupling, 76
 rod-rod coupling, 75–76
 signals, circuitry
 through, 39–41
 synaptic terminal,
 calcium concentration
 at, 77
 vs. cone b-wave, 109
 spectral sensitivity
 functions, 476
 S
 Santavuori-Haltia
 lipofuscinosis, 786
 Scattergrams: for scotopic
 responses, 377
 Scatterplots: in retinitis
 pigmentosa, 519, 520
 Schisis: macular, vs. edema,
 fluorescein
 angiography in,
 496–497
 Sclerosis (*see* Multiple
 sclerosis)
 S-cone syndrome, 680
 Scotoma
 with cone degeneration
 and familial drusen,
 680
 ring, 518
 Scotopic b-wave: in diabetic
 retinopathy, 622–623
 Scotopic/photopic
 equivalence, 202–203
 Scotopic responses:
 scattergrams for, 377
 Scotopic threshold response,
 121–124
 characteristics of, 353–355
 clinical applications, 360
 comparison between
 species, 355–356
 contribution to ERG, 122
 dominating intraretinal
 recordings, 122
 of electroretinography,
 352–362
 history of, 352–353
 intraretinal recordings (in
 cat), 356
 K⁺-Müller cell mechanism
 for, 122–123
 latency decreasing, 354
 pharmacology of,
 357–358
 physiology, 358–359
 quantal sensitivity of, 358
 recording tips for clinical
 patients, 359–360
 retinal gain in, 358–359
 retinal origins of, 356–357
 rod pathway in starlight,
 358
 as separate response,
 121–122
 depth distribution,
 121–122
 intensity, 122
 in vision loss and
 intraocular pressure
 elevation, 360
 V-log I curve of, 353
 waveform interaction with
 PII, 355
 Scotopic vision: lacking
 spatial sensitivity, 359
 Senile dementia: of
 Alzheimer's type,
 pattern
 electroretinography in,
 795
 Sex: effect of, in
 electroretinography,
 377
 Signal analysis, 232–237
 delay, 234–235
 distortion, 235–237
 frequencies, two
 harmonically related,
 234
 frequency dependence,
 232–234
 latency, 234–235
 linearity, 232
 minimum-phase rule,
 234–235
 phase shifts, 234
 square wave pattern, 236

- Signal-noise ratio:
improvement with averaging, 149–150
- Silent substitution, 202–203
- Sine wave, 233
- Sinusoidal grating, 466
- Sinusoidally flickered test stimulus: illuminance of, 470
- Skin electrodes, 180
- Small signals: averaging, 389–390
- Sorsby's fundus dystrophy, 705
diagnosis, differential, 706
electrophysiology of, 706
histology, 706
pathogenesis, 706
- Spastic paraplegia (*see* Paraplegia, spastic)
- Spatial contrast, 467
sensitivity, 468
- Special-purpose data acquisition systems, 188–192
characteristics of, general, 189–191
questions about, 191–192
- Spreading depression, 130
- Square wave, 238, 240
flickering test probe: luminance of, 471
infinite, line spectrum of, 242
pattern, 236
- Stargardt's disease, 669–674 (*See also* Fundus flavimaculatus)
age of onset, 669–670
angiography of, fluorescein, 670, 671–672
dark choroid effect in, 498
diagnosis, differential, 674
fundus in, 670–671
history, 669
inheritance of, 669
pathogenesis, 673
pathology, 673
prognosis, 673–674
visual acuity in, 670
visual function in, 672–673
- Stengel-Spielmeyer-Vogt lipofuscinosis, 788–789
- Stereopsis: in infant, 410
- Sternomastoid tremor, 406
- Stimulation
Ganzfeld, 214–215, 332
local, for electrophysiology, 215
pattern-onset, and defocusing, 439
- Stimulator(s)
for electrophysiology, 224–226
electroretinography, 224–226
visual evoked response, 224
flash, voltage drive circuit for, 223
Ganzfeld, 371–372
maxwellian-view ophthalmoscope, 373
- Stimulus
color (*see* Color stimuli)
devices, 211–220
/response function, 261
- Sweep (*see* Visual evoked potential, sweep)
- Synapse: first, signal shaping at, 76–81
- Synaptic
gain of postsynaptic cells, 80–81
postsynaptic (*see* Postsynaptic)
terminal of rod, calcium concentration at, 77
- Synchronous amplification, 250–252
- ## T
- Telangiectasia: disc, with optic atrophy, 499
- Telodendria: of cone pedicles, gap junction between two, 31
- Temporal contrast, 466–467
- Temporal frequency
characteristics: and aging, 420
- Ten-twenty
designated positions, plan view of, 402
designations of electrode position, 402–406
method of measurement, 400–401
system
circumference location of, 401
lateral locations of, 401
- Testing: clinical, principles, 483–569
- Theory: duplicity, 448–449
- Thioridazine
NP207 and, 600–604
clinical findings, 600–601
physiological testing, 602–603
retinopathy, 600–606
adaptometry in, dark, 604
early, 601
ERG in, 603
late, 602
stable vs. progressive, 601–602
toxicity mechanism, 603–604
visual field changes in, 604
- Thorazine, 605
- Threshold
absolute, 445
determination methods
critique of, 445–448
visual channels and, 448
difference, 445–446
scotopic (*see* Scotopic threshold)
term, discussion of, 445
- Topographical evoked potential mapping (*see* Mapping, topographical evoked potential)
- Toxicity
corneal, 594
drug, pathogenesis, 598
retinal, 565–610
chloroquine causing, 594–599
functional problems, 565–610
hydroxychloroquine causing, 594–599
monitoring for, 596–598
phenothiazine, 600–606
practical problems, 565–610
risk of, 596
thioridazine (*see* Thioridazine, retinopathy)
- Tranquilizers: minor, and visual nervous system, 169
- Transmitter release: control by membrane potential, 76–77
- Trauma: ocular, evaluation, opaque media, 567–572
- Tremor: sternomastoid, 406
- Tubes
cathode ray, 218
display (*see* Display tubes)
- Tumors:
electrophysiological evaluation, 611–645
- ## U
- Ultrastructure
in Bietti's crystalline dystrophy, 689, 690
in lipofuscinosis, neuronal ceroid, 789
- Usher syndrome: type I, fluorescein angiography in, 496
- ## V
- Vein, retinal (*see* Retina, vein)
- VEP (*see* Visual evoked potential)
- Vernier acuity: in infant, 409–410
- Vessels
disease,
electrophysiological evaluation, 611–645
retinal (*see* Retina, vessels)
- Vinca alkaloids: and retina, 159–160
- Vision
color (*see* Color vision)
loss
nonorganic, PVEP and PERG in, 574
scotopic threshold response in, 360
scotopic, lacking spatial sensitivity, 359
- Visual acuity
(*See also* Acuity)
charts according to international recommendation, 461
decrease in multiple sclerosis, 806–807
development, and sweep VEP, 411
estimation in infants (*see* Infant, visual acuity estimation in)
as function of luminance, 460
in Leber's hereditary optic atrophy, 763
low-contrast, 462
low-contrast tests, practical value of, 462–463
in multihandicapped patients, 463
in night blindness, incomplete-type, 721, 724
in retinitis pigmentosa, 520
in Sorsby's fundus dystrophy, 705
of Stargardt's disease, 670
testing, luminance in, 459–460

- testing principles, 459–464
 - tests, 460–462
 - tests, optotype, 460–462
 - tests, standardization of situations, 463
 - angles, calculation of, 203
 - channels and threshold determination methods, 448
 - delayed maturation (*see* Developmental delay)
 - development
 - control by visual experience, 412–413
 - results in, recent, 412–414
 - dysfunction in multiple sclerosis, 806–809
 - electrophysiology (*see* Electrophysiology)
 - evoked potential(s)
 - amplitude of, 233
 - cortical (*see below*)
 - drugs decreasing amplitude, 168
 - drugs increasing amplitude, 168
 - flash, cutoffs and, 188
 - flash, in multiple sclerosis, 799
 - flash, during optic nerve glioma surgery, 609
 - latency in infant, 410–411
 - monitoring with,
 - intraoperative and intensive care unit, 607–610
 - in normal adult, 133
 - occipital, to sinusoidally modulated light, 236
 - in parkinsonism, 811
 - pattern, in multiple sclerosis, 798
 - pattern reversal, 136–141
 - pattern reversal, normal, 140
 - pattern reversal, waveforms, 136–141
 - phase characteristics of, 233
 - relation to acuity, 136
 - source derivations of stimulation and, 137
 - steady-state, in infant, 411
 - stylized, to flash stimulation in adults, illustration, 18
 - during surgery, 608
 - sweep contrast sensitivity, 414
 - sweep technique in infant, 411–412
 - topography in albinism, 430
 - transient, in infant, 410
 - evoked potentials, cortical, 397–441
 - age changes in, 417–420
 - aging and, 417–424
 - in albinism (*see* Albinism)
 - basic recording, 399–407
 - in blindness, cortical (*see* Blindness, cortical, visual evoked cortical potentials in)
 - with chromatic stimuli, 147–150
 - with chromatic stimuli, clinical data, 148
 - color, to appearance, 147–148
 - color, to reversal and motion, 148
 - in developmental delay, 581–584
 - in diabetic retinopathy, 625
 - electrodes for, 399
 - electrodes, placement, 399–406
 - flash, in developmental delay, 585–588
 - in Leber's hereditary optic atrophy, 764
 - in multiple sclerosis (*see* Multiple sclerosis, visual evoked cortical potential in)
 - origin of components, 132–144
 - pattern-reversal, 419
 - pattern-reversal responses, 418
 - recording, artifact recognition, 438–439
 - recording, diurnal patterns, 438
 - recording, interest variability, 438
 - recording, normative studies, 437–438
 - recording, patient compliance, 439–440
 - recording, stimulus conditions, 435–437
 - recording, technical issues in, 435–441
 - testing, history of, 17–22
 - for visual acuity
 - estimation in infants (*see* Infant, visual acuity estimation in, by visual evoked cortical potentials)
 - evoked response
 - electrodes, 181
 - flash, 132–136
 - flash, distribution of P1 and P2 components, 135
 - flash, scalp localization, 133–136
 - flash, waveform, 132–133
 - stimulators for, 224
 - experience, visual development control by, 412–413
 - field(s)
 - changes in thioridazine retinopathy, 604
 - defects in multiple sclerosis, 808–809
 - in Leber's hereditary optic atrophy, 763–764
 - in night blindness, incomplete-type, 721
 - function
 - change in retinitis pigmentosa, 505–506
 - in Stargardt's disease, 672–673
 - tests, 487
 - tests, diseases where tests are informative, 487
 - tests, information obtained, 487
 - loss (*see* Vision loss)
 - nervous system (*see* Nervous system, visual)
 - performance
 - contrast sensitivity in, 413–414
 - tasks, 408–410
 - tasks, uses of, 408–410
 - signals and physiological noise, 184
 - system, testing levels of, 485
 - testing in infant (*see* Infant, visual acuity estimation in)
 - recording, technical issues in, 435–441
 - testing, history of, 17–22
 - for visual acuity
 - estimation in infants (*see* Infant, visual acuity estimation in, by visual evoked cortical potentials)
 - evoked response
 - electrodes, 181
 - flash, 132–136
 - flash, distribution of P1 and P2 components, 135
 - flash, scalp localization, 133–136
 - flash, waveform, 132–133
 - stimulators for, 224
 - experience, visual development control by, 412–413
 - field(s)
 - changes in thioridazine retinopathy, 604
 - defects in multiple sclerosis, 808–809
 - in Leber's hereditary optic atrophy, 763–764
 - in night blindness, incomplete-type, 721
 - function
 - change in retinitis pigmentosa, 505–506
 - in Stargardt's disease, 672–673
 - tests, 487
 - tests, diseases where tests are informative, 487
 - tests, information obtained, 487
 - loss (*see* Vision loss)
 - nervous system (*see* Nervous system, visual)
 - performance
 - contrast sensitivity in, 413–414
 - tasks, 408–410
 - tasks, uses of, 408–410
 - signals and physiological noise, 184
 - system, testing levels of, 485
 - testing in infant (*see* Infant, visual acuity estimation in)
 - Vitamin A deficiency, 737–740
 - adaptometry in, two-color dark, 739
 - electroretinography in, 738
 - fundus photograph in, 738
 - rhodopsin in, 739
 - Vitreous
 - hemorrhage, effect on electroretinography, 379
 - humor, electrode in (in cat), 109
 - substitute, effect on electroretinography, 379–380
 - V-log intensity curves, of b-wave amplitudes, 154
 - Voltage calibration, 382
- ## W
- Waveform
 - aging and, changes, 417
 - electroretinographic (*see* Electroretinography, waveform)
 - White-dot syndromes, 640–642
 - "multiple evanescent," 641
- ## X
- Xenon
 - flash lamp, 213
 - time course of light output, 214
 - sources for stimulation, 211–214
 - X-linked
 - choroideremia carrier state evaluation, 744–747
 - inherited conditions and suppressive rod-cone interaction, 472
 - recessive
 - cone dystrophy (*see* Cone dystrophy, X-linked recessive)
 - congenital stationary night blindness, 711
 - pedigree in
 - choroideremia, 495
 - retinitis pigmentosa, female carriers, ERG detection, 741–743
 - retinitis pigmentosa, 504
 - retinoschisis (*see* Retinoschisis, X-linked)